Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.
Mocciaro
Filippo
F
Renna
Sara
S
Orlando
Ambrogio
A
Cottone
Mario
M
D017255:Acitretin / Q000627:therapeutic use; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003092:Colitis / Q000175:diagnosis / Q000188:drug therapy; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D018570:Risk Assessment; D012720:Severity of Illness Index
D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D017255:Acitretin; D000068582:Certolizumab Pegol